A 24-hour before · 72-hour after frame
Practical, non-prescriptive nutrition and hydration considerations for the period around iboga-assisted care—where supervision, tolerance, and escalation matter more than a rigid protocol.
Explore the care windowA bounded care window
Peri-session care covers the practical period from roughly 24 hours before through 72 hours after an iboga-assisted session. It is not a standalone nutrition plan, and it cannot replace the instructions, monitoring, or escalation pathway established by the supervising team.
For an overview of the wider topic, the Nutriboga: Nutrition Around Iboga-assisted Care resource places this period alongside preparation and recovery considerations. The working aim here is simpler: maintain an observable, tolerable approach to intake while avoiding preventable strain when nausea, fatigue, fasting, or appetite changes are present.
Before and during
Hydration planning should be controlled rather than aggressive. The supervising team may specify fasting, fluid limits, timing, or medications that change what is appropriate. Follow those instructions rather than using generalized targets. If fluids are permitted, small tolerated amounts are usually easier to observe than large volumes taken at once.
Nausea and vomiting can make oral intake unreliable. Do not attempt to “push through” with food or fluids when swallowing is unsafe, vomiting is ongoing, alertness is altered, or the medical team has instructed that oral intake be withheld. A care team should direct the timing and method for restarting intake.
Nausea and refeeding
After prolonged fasting or vomiting, restart only when the supervising team says oral intake is appropriate and tolerance has returned. Begin with modest, familiar choices that are easy to evaluate for comfort and tolerance; progress in response to symptoms rather than trying to make up for missed food immediately.
Electrolyte disturbances can become clinically important when fluid losses or inadequate intake are substantial. The National Institute of Diabetes and Digestive and Kidney Diseases guidance on vomiting-related fluid loss notes the importance of replacing fluids and electrolytes, while severe or persistent symptoms require medical evaluation. In a peri-session setting, defer product choices, quantities, and timing to the medical team.
Report inability to keep down liquids, repeated vomiting, severe weakness, confusion, fainting, worsening abdominal symptoms, or signs that intake is not being absorbed or tolerated. These are escalation points—not reasons to layer in new foods, supplements, or home remedies.
After the session
Constipation, reduced appetite, and irregular eating can appear after a session. If the clinical team considers oral intake appropriate, regular small meals and permitted fluids may be easier to manage than a large catch-up meal. Gentle food texture and routine can be practical considerations, but they should not override individual restrictions, symptom changes, or medical directions.
Appetite can return unevenly. The immediate goal is tolerability and adequate observation, not dietary perfection. Sleep and mood can also be unsettled during recovery; avoid treating this as a reason to introduce stimulating products, unreviewed herbal blends, or sudden dietary experiments.
“If intake is limited, symptoms are worsening, or dehydration is suspected, the next step is clinical reassessment—not nutritional improvisation.”
Interactions and limits
Evidence for specific nutrition or supplement protocols around iboga-assisted care is limited. This makes a conservative approach important: do not add supplements simply because they are marketed for energy, detoxification, sleep, mood, nausea, or recovery. Products that may affect cardiac rhythm, blood pressure, alertness, metabolism, or medication handling warrant explicit review by the supervising medical team.
QT prolongation refers to a change on an electrocardiogram associated with risk of dangerous rhythm disturbances in some settings; the overview of long QT syndrome provides useful background on why rhythm-related risk matters. Avoid assuming that a “natural” product is neutral, especially if it is described as QT-prolonging or has not been reviewed for interaction risk.
The page on drug-nutrient interactions and considerations offers a focused place to organize questions about products, medications, and timing before acting on them. For people seeking broader context on ibogaine-related concerns, the ibogaine opioid-addiction information resource may help frame why medically supervised decision-making is central.
Practical handoff
Before the session, identify who decides when oral intake is held or restarted, what symptoms trigger reassessment, and how the team wants vomiting, fluid tolerance, bowel changes, and appetite changes reported.
During the 72-hour recovery period, report possible electrolyte issues, severe dehydration, persistent constipation with concerning symptoms, or an inability to tolerate oral intake promptly. The guide’s information pathways can help people organize topics for a discussion, but they do not replace individualized medical assessment.
For scope, sourcing, and the independent purpose of this resource, see how Nutriboga Nutrition Guide approaches its information.
Common decision points
Oral intake should be deferred when the supervising medical team instructs it, when swallowing is unsafe, when vomiting is ongoing, or when altered alertness makes intake unreliable. The clinical team should determine when and how to restart fluids or food.
IV fluids are a clinical decision when oral intake cannot be tolerated or dehydration and electrolyte concerns need assessment. They are not a substitute for evaluation by the supervising medical team.
Do not assume a supplement is appropriate because it is sold for sleep, mood, nausea, or recovery. Review every product with the supervising team, particularly anything that could affect rhythm, sedation, blood pressure, or medication metabolism.
Escalate persistent vomiting, inability to tolerate fluids, marked weakness, fainting, confusion, severe dehydration concerns, or suspected electrolyte abnormalities to the supervising medical team without delay.